Kyprolis 30mg (Carfilzomib Vials) 30mgx15ml

Kyprolis 30mg is a prescription medication used in cancer treatment, specifically for multiple myeloma. Available as 30mg vials, it is administered intravenously and requires refrigeration. This chemotherapy drug targets cancer cells to slow disease progression.

Strength

30mgx15ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Amgen

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Carfilzomib, the active ingredient in Kyprolis 30mg, is used to treat patients with multiple myeloma, a type of blood cancer. It is often prescribed after other treatments have been tried. The medication works by blocking enzymes that help cancer cells grow and survive. Kyprolis is typically used in combination with other cancer drugs for better results.

Side Effects

Kyprolis 30mg helps reduce the growth of cancer cells in the body, which may slow the progression of multiple myeloma. Patients may experience improved energy levels and reduced symptoms related to their condition. The effects vary by individual, and regular monitoring by a healthcare provider is recommended.

Precautions & Warnings

Kyprolis should be handled with care, as it is a chemotherapy drug. It must be stored at 2-8°C and protected from light. Avoid direct contact with the skin or eyes; if exposure occurs, rinse thoroughly with water. Always follow your healthcare provider’s instructions for safe use and disposal.

Avoid Interactions

Kyprolis may interact with other medications, including certain blood pressure drugs, antibiotics, and herbal supplements. Alcohol and grapefruit products should be avoided while using this medication. Always inform your doctor about all medications and supplements you are taking to prevent potential interactions.

Frequently Asked Questions

Kyprolis 30mg is used to treat multiple myeloma, a type of blood cancer, in patients who have tried other treatments.

Kyprolis 30mg is given as an intravenous injection by a healthcare professional in a clinical setting.

Avoid alcohol, grapefruit, and other medications unless approved by your doctor to prevent interactions.

Store Kyprolis 30mg vials at 2-8°C and protect them from light until ready for use.

Kyprolis may harm an unborn baby; discuss pregnancy risks with your healthcare provider before use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.